Menu Search
Equities

Aethlon Medical Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
0A6R:LSE

Aethlon Medical Inc

Actions
  • Price (EUR)--
  • Today's Change--
  • Shares traded--
  • 1 Year change--
  • Beta1.6133
Data delayed at least 20 minutes.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Aethlon Medical, Inc. is a clinical-stage medical device company. The Company is focused on advancing the Hemopurifier (HP), a clinical-stage immunotherapeutic device intended for applications in cancer, life-threatening viral infections, and organ transplantation and other areas of significant unmet needs. In pre-clinical studies, the Hemopurifier has exhibited the capacity to remove harmful extracellular vesicles (EVs) and enveloped viruses from biological fluids, utilizing its proprietary lectin-based mechanism. These extracellular vesicles have been implicated in disease processes such as immune suppression and metastasis in cancer as well as in the progression of severe life-threatening infectious diseases. The United States Food and Drug Administration (FDA) has designated the Hemopurifier as a Breakthrough Device for the treatment of individuals with advanced or metastatic cancer who are unresponsive to or intolerant of standard of care therapy.

  • Revenue in USD (TTM)0.00
  • Net income in USD-11.26m
  • Incorporated1991
  • Employees9.00
  • Location
    Aethlon Medical Inc11555 Sorrento Valley Road, Suite 203SAN DIEGO 92121United StatesUSA
  • Phone+1 (619) 941-0360
  • Fax+1 (619) 941-0361
  • Websitehttps://www.aethlonmedical.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.